Erratum to “Incorporation of alemtuzumab into frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study”
{"title":"Erratum to “Incorporation of alemtuzumab into frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study”","authors":"","doi":"10.1002/cncr.35803","DOIUrl":null,"url":null,"abstract":"<p>This erratum corrects the following:</p><p>Luskin MR, Yin J, Lozanski G, et al. Incorporation of alemtuzumab into frontline therapy of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study. <i>Cancer.</i> 2025;131(4):e35750. doi:10.1002/cncr.35750</p><p>The article ’s title was originally published in truncated fashion (“Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study”). The revised full title appears below and should read: “Incorporation of Alemtuzumab into Frontline Therapy of Adult Acute Lymphoblastic Leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study.” The full title as listed above is correct.</p><p>We apologize for this error.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 6","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35803","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer","FirstCategoryId":"3","ListUrlMain":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35803","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
This erratum corrects the following:
Luskin MR, Yin J, Lozanski G, et al. Incorporation of alemtuzumab into frontline therapy of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study. Cancer. 2025;131(4):e35750. doi:10.1002/cncr.35750
The article ’s title was originally published in truncated fashion (“Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study”). The revised full title appears below and should read: “Incorporation of Alemtuzumab into Frontline Therapy of Adult Acute Lymphoblastic Leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study.” The full title as listed above is correct.
本勘误表更正了以下错误：Luskin MR， Yin J, Lozanski G, et al.。将阿仑单抗纳入成人急性淋巴细胞白血病的一线治疗：Cancer and leukemia Group 10102 （Alliance）的1/2期研究结果癌症。2025;131 (4):e35750。doi: 10.1002 / cncr。该文章的标题最初以截尾形式发表（“Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study”）。修订后的全文如下，应该阅读：“将阿仑妥珠单抗纳入成人急性淋巴细胞白血病的一线治疗：癌症和白血病B组10102（联盟）的结果，1/2期研究。”上面列出的完整标题是正确的。我们为这个错误道歉。
期刊介绍：
The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society.
CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
